CXCL10 and cancer: Predominantly, these data indicate that administration of AVA-NP-695 could suppress the mesenchymal markers, thereby blocking metastasis, and also inducing expression of IFN-β and CXCL-10 necessary to activate T cell-mediated anti-tumor efficacy, thus exhibiting a potential characteristic of a cancer immunotherapy.